Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung

Filip Baszkowski1, Weronika Pelczar-Płachta1, Nikola Pempera1

  • 1Department of Pediatric Cardiology, Poznan University of Medical Sciences, 60-572 Poznan, Poland.

PubMed

Insights

This case study highlights the challenges in diagnosing and treating pediatric idiopathic pulmonary arterial hypertension (IPAH). Early symptom recognition and intensive treatment are crucial for better outcomes in children with IPAH.

Area of Science:

  • Pediatric Cardiology
  • Pulmonology
  • Rare Diseases

Background:

  • Pulmonary arterial hypertension (PAH) is a rare, heterogeneous disorder in children, often linked to congenital heart disease.
  • Managing pediatric idiopathic PAH (IPAH) is challenging due to limited comparative data and reliance on adult studies and expert experience.

Purpose of the Study:

  • To present a case of a 9-year-old girl with IPAH, detailing her treatment journey.
  • To emphasize the importance of early symptom identification and prompt, intensive treatment in pediatric PAH.
  • To share insights on diagnostic and treatment approaches for challenging pediatric cases.

Main Methods:

  • The case involved a 9-year-old girl diagnosed with IPAH after a prolonged diagnostic process.
  • Treatment included pharmacotherapy with treprostinil, featuring rapid dose escalation similar to adult protocols.
  • The patient ultimately underwent bilateral lung transplantation.

Main Results:

  • The patient showed a significant response to treprostinil therapy.
  • Rapid dose escalation, mirroring adult treatment, was employed.
  • The case underscores the complexity of diagnosing and managing pediatric IPAH.

Conclusions:

  • Diagnosis of pediatric PAH can be lengthy due to non-specific symptoms, necessitating thorough differential diagnosis.
  • Treatment initiation for pediatric IPAH is often individualized due to limited evidence.
  • This case illustrates the potential utility of intensive treatment strategies and diagnostic methods in complex pediatric cases.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
236
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
194
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
164